> ## Content Index > Fetch the complete content index at: https://nexi.fund/llms.txt > Use this file to discover other available public pages before exploring further. # GOA Therapeutics Bets $15.5M That Alcohol Can Be Cleared Faster - URL: https://nexi.fund/goa-therapeutics-goa26-alcohol-intoxication-2026/ - Published: 2026-09-19T11:00:19.000Z - Updated: 2026-09-19T11:00:19.000Z - Description: A Dallas biotech left stealth with $15.5 million and a first-in-class candidate designed to lower blood alcohol in the emergency department. The preclinical number is striking. The human question is open. - Author: Nexi.fund Labs - Tags: Biotech & Health, #mode-5, #hook-paradox, #track-E, #brand-heavy Someone is wheeled into an emergency department with a blood alcohol concentration high enough to suppress breathing. The team can protect the airway, give fluids and vitamins, and in the most severe cases escalate to intensive care. What they cannot do is make the alcohol go away faster. No drug approved by the U.S. Food and Drug Administration (FDA) rapidly lowers blood alcohol in a patient who is already intoxicated. That gap is the entire thesis of GOA Therapeutics, a Dallas company that came out of stealth on Sept. 17 with $15.5 million and a lead candidate named GOA26. ``` TIMELINE: GOA26's path to the clinic ───────────────────────────────────────────────────────────── 2024–2026 ──────── Sept 2026 ──────── Q4 2026 ──────── 2027 🔬 ◉ NOW 🧪 🏥 Preclinical work AAST data FDA IND filing First human under stealth + $15.5M planned trials planned ``` Company statements and BioWorld, September 2026\. Human trial start is subject to regulatory clearance. ## What GOA26 claims to do GOA26 is being developed as an intravenous (IV) therapy for acute alcohol intoxication and poisoning. The company's framing is about speed: clear the alcohol before it does lasting harm. At the American Association for the Surgery of Trauma (AAST) annual meeting, GOA presented results from an IND-enabling porcine study. Blood alcohol concentration was 61.3% lower in treated animals than in the untreated control group 20 minutes after dosing. That is the number the company is leading with. It is also the only efficacy figure it has published so far. 61.3% lower BAC vs control #### Blood alcohol reduction in pigs At 20 minutes post-dose in an IND-enabling porcine model · *Company data presented at AAST, 2026* There is no peer-reviewed paper behind the figure yet, only a conference presentation and a press release. The company has not disclosed how many animals were studied, at what dose, or whether the effect held beyond the 20-minute mark. ## Pigs are not people This is where the biotech record should make an investor slow down. A stealth company, one striking animal dataset, a modest early round. The shape is familiar. Sometimes it becomes a platform. Often it becomes a cautionary tale. Animal models do not always predict human results. Pigs are a reasonable large-animal model, and the biology differs enough across species to matter. A 61.3% drop in a controlled study still does not translate automatically into a hospital outcome. The endpoint that matters in humans is not a concentration curve. It is whether patients do better — fewer intubations, shorter stays, fewer deaths. 🎯 GOA26 addresses a real and narrow gap: no approved drug rapidly clears alcohol from the blood. The evidence so far is preclinical, company-reported and not yet peer-reviewed. The next true checkpoint is an FDA filing in the fourth quarter of 2026, not a product. ## The team behind the pitch GOA is led by Andrew Altschuler as co-founder and chief executive, with Tami Ehrmann Barr, a physician and scientist, as co-founder and chief scientist, and Dean Hakanson, also a physician, as chief medical officer. The company says it will introduce the wider team in the coming months. A stealth biotech's roster is part of its evidence. The names, and the institutions behind them, are how a small company signals that it can navigate trials and regulation. GOA has shown three names so far. ## A narrow lane, not the whole market Two different businesses get confused here. Alcohol use disorder — chronic dependence — is treated with a different class of drugs. Acute intoxication and poisoning is a separate, emergency-medicine problem. GOA is aimed at the second. The choice is deliberate. Emergency departments need something that works within minutes, and no incumbent owns that space. The same choice carries risk. A narrow indication can mean a faster approval path and an obvious clinical need. It can also mean a limited market, a hard payer conversation, and a product only some hospital systems will stock. #### The questions GOA26 still has to answer Does the effect scale to humans, and at what dose? What happens to the alcohol once it is cleared — where does it go? Can the company show fewer intubations or shorter stays, not just a lower number? Who is funding the next round, and at what valuation? **Confirmation criteria:** a peer-reviewed publication and a named investor syndicate. ## The catalyst is a filing, not a cure GOA plans to submit an investigational new drug (IND) application to the FDA in the fourth quarter of 2026, with human trials beginning in 2027 if regulators clear it. Those are the dates to hold the company to. Between now and then, the signals that matter are concrete. A scientific publication. A disclosed investor base. Hiring in clinical operations. 📊 **Key signals to track** An IND filing in Q4 2026, met or missed A peer-reviewed version of the 61.3% dataset Named investors and the size of the next round The design and endpoint of the first human study GOA26 is not a cure for alcohol use disorder, and it is not trying to be. It is a bet that emergency medicine will pay for a fast way to clear a substance that today has to be waited out. That bet is plausible. It is also unproven. ## Sources [ GOA Therapeutics unveils GOA-26 for acute alcohol poisoning Trade coverage of the stealth emergence and the intravenous positioning of GOA26 in emergency departments. BioWorld ](https://www.bioworld.com/articles/734154-goa-therapeutics-unveils-goa-26-for-acute-alcohol-poisoning?ref=nexi.fund) The clearest independent framing of where GOA26 would be used: hospital emergency departments. [ GOA Therapeutics emerges from stealth with $15.5 million The primary company release: funding, the AAST preclinical data, and the planned Q4 2026 IND filing. GlobeNewswire ](https://www.globenewswire.com/news-release/2026/09/17/3364356/0/en/goa-therapeutics-emerges-from-stealth-with-15-5-million-in-funding-and-unveils-goa26-a-first-in-class-drug-candidate-for-acute-alcohol-intoxication-and-poisoning.html?ref=nexi.fund) Source of the 61.3% figure and the timeline. Treat the efficacy claim as company-reported until it is published. [ GOA Therapeutics corporate site The company's own framing of GOA26 and its three named executives. GOA Therapeutics ](https://goathera.com/?ref=nexi.fund) Useful for team composition and positioning; carries no independent verification.